검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunomodulatory (IM, Adjuvant Immunomodulatory, Adjuvant Immunomodulatory (IM) Therapy) Ultragenyx Pharmaceutical Inc·Mucopolysaccharidosis IIIA 74 trials |
|---|---|
Overview Program | Adjuvant Immunomodulatory (IM) Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis IIIA |
Overview Indication | Mucopolysaccharidosis IIIA; MPS IIIA |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | bispecific antibodies and pairwise interactions in antibody-dependent cell cytotoxicity events |
MoA Biomarker | biomarker levels were compared between groups |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Gastroscopic Evaluation of Gastric Mucosa in Horses Treated With Flunixin Meglumine or High-Dose Firocoxib: A Descriptive Pilot Study.. Equine Gastric Ulcer Syndrome (EGUS) is common in horses, and nonsteroidal anti-inflammatory drugs (NSAIDs) are a known risk factor for gastrointestinal ulceration. Although COX-2 selective NSAIDs such as firocoxib theoretically offer a better safety profile, endo… |
Clinical PFS | 314 |
Clinical OS | 913 |
Clinical Result source | ClinicalTrials.gov NCT03334305 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunomodulatory (IM, Adjuvant Immunomodulatory, Adjuvant Immunomodulatory (IM) Therapy) Ultragenyx Pharmaceutical Inc·Mucopolysaccharidosis IIIA 74 trials |
|---|---|
Overview Program | Adjuvant Immunomodulatory (IM) Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis IIIA |
Overview Indication | Mucopolysaccharidosis IIIA; MPS IIIA |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | bispecific antibodies and pairwise interactions in antibody-dependent cell cytotoxicity events |
MoA Biomarker | biomarker levels were compared between groups |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Gastroscopic Evaluation of Gastric Mucosa in Horses Treated With Flunixin Meglumine or High-Dose Firocoxib: A Descriptive Pilot Study.. Equine Gastric Ulcer Syndrome (EGUS) is common in horses, and nonsteroidal anti-inflammatory drugs (NSAIDs) are a known risk factor for gastrointestinal ulceration. Although COX-2 selective NSAIDs such as firocoxib theoretically offer a better safety profile, endo… |
Clinical PFS | 314 |
Clinical OS | 913 |
Clinical Result source | ClinicalTrials.gov NCT03334305 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교